Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly, Novo Nordisk
Novo beats Eli Lilly in Q3 sales for obesity drug
Novo Nordisk (NVO) reported better than expected sales for its weight loss therapy Wegovy with its Q3 2024 financials on Wednesday after Eli Lilly (LLY), its rival in the obesity drug market, posted a rare quarterly miss for its GLP-1 drug,
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the consensus estimates.
Novo Nordisk’s Blockbuster Wegovy Drug Sales Beat Expectations
The pharmaceutical giant’s blockbuster weight-loss drug beat sales expectations in the third quarter, sending shares higher in early trade.
BioSpace
1h
While Lilly Blames Wholesalers for Slow GLP-1 Sales, Novo’s Rival Medicine Is Flowing
Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.
2d
on MSN
How does Viking's weight loss med compare to ones from Novo, Eli Lilly?
Data reported earlier Monday from Viking Therapeutics (NASDAQ:VKTX) on its weight loss medicine VK2735 indicates that Novo ...
6d
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Even with this partial rebound,
Lilly
's share price remains roughly 13% below the peak set in late August. Some investors ...
2d
Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy Right Now?
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
7d
on MSN
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
6d
Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round up
Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...
salisburypost
12h
RCCC benefits from involvement with Eli Lilly and Company’s Global Day of Service
RCCC News Service SALISBURY — Rowan-Cabarrus Community College and its students recently benefited from involvement with Eli Lilly and Company and its annual Global Day of Service. Student ...
7d
on MSN
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
The Associated Press - Business News on MSN
8d
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
8d
Is Eli Lilly Stock a Buy?
However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...
17h
on MSN
Eli Lilly Posts a Huge Earnings Miss. Should Investors Be Worried?
Eli
Lilly
's business is growing fast, but it wasn't enough for analysts and investors. It also slashed its earnings ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Novo Nordisk
Zepbound
Mounjaro
Wegovy
Vikings
Feedback